CDEK by Data4ThePeople

Sign in Sign up

← All drugs Report issue

afacifenacin

Small moleculeexperimental

Clinical trial activity

1 trials · 7 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Dec 1, 2006 (NCT00409539)

Timeline

2000s

Jan 1, 2006
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Urinary Bladder, Overactive · Phase 2

Mechanism of action

Muscarinic acetylcholine receptorANTAGONIST
Muscarinic acetylcholine receptor antagonist
Non-selective muscarinic receptor antagonist and sodium channel blocker.
Sodium channel protein type X alpha subunitBLOCKER
SCN10A blocker
Non-selective muscarinic receptor antagonist and sodium channel blocker.
- Sodium channel protein type 10 subunit alpha (SCN10A) ↗
Sodium channel protein type XI alpha subunitBLOCKER
SCN11A blocker
Non-selective muscarinic receptor antagonist and sodium channel blocker.
- Sodium channel protein type 11 subunit alpha (SCN11A) ↗

Chemistry & pharmacology

Loading structure…

SMILES

O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

Mol. weight: 481.52 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545165 ↗

Also known as

afacifenacin
afacifenacin
ns-986
ns-986
smp-986
smp-986
smp-986

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00409539	Phase 2	Dec 1, 2006	ClinPhone, Inc., Covance, ICON, PPD, Sheffield Hallam University, Sumitomo Dainippon, Sunovion

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (7)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
ClinPhone, Inc.	For profit	1	0	1	2006
Covance	For profit	1	0	1	2006
ICON	For profit	1	0	1	2006
PPD	For profit	1	0	1	2006
Sheffield Hallam University	Academic/Hospital	1	0	1	2006
Sumitomo Dainippon	For profit	1	0	1	2006
Sunovion	For profit	1	1	1	2006

7 organizations

Page 1 / 1